Ian Hayes Email and Phone Number

Progressive 5+ year senior management career, shaping commercial strategy, product transformation, driving growth and operational excellence for new Cell Analysis division of global life sciences leader Agilent Technologies Inc., following successful acquisition of Irish biotech start-up Luxcel Biosciences. LEADERSHIP & STRATEGY:• Transformed product marketing and lifecycle process, instilling a commercialization mindset, aligning strategy, best practice and matrix partnership between marketing, R&D, manufacturing and sales. • Shaped and expanded product roadmap, cultivating cross-product line synergies across the division, opening up new high growth markets in cell & gene therapy and drug discovery; delivering continuous profitable growth and leading market share. • Led development and launch of Agilent Seahorse XF Pro instrument and associated kits, labware and applications; voted ‘Best New Drug Discovery & Development Product’ at 2022 Select Science Scientists’ Choice Awards. • Redefined the customer journey through application-based content and led highly effective digital marketing and eCommerce transition, navigating the business through its most challenging years including the global pandemic.• Cross-functional strategic leadership of global initiative to transition Cell Analysis business from core academia markets into pharma/biopharma, increasing market share from 10% to 30%. PEOPLE MANAGEMENT:• Recruited, developed and mentored a highly effective and respected global team of product managers, with portfolio responsibility for a broad range of cell analysis instruments, kits & assays, software analytics and specialty microplates. • Developed a highly collaborative marketing communications team, based across USA, Europe & China, with global responsibility for marketing communications strategy and execution, including product and application web page content, marketing automation, global and regional marketing campaigns and conferences.

Provided 10+ years strategic management expertise, leading and delivering technology commercialization with the Irish Biotech, Medtech, Food and Diagnostics industry. The following are a representative selection of my roles:OPSONA THERAPEUTICS LTD (2007-2019) | DRUG DEVELOPMENT | BUSINESS DEVELOPMENT & LICENSING• Developed commercial strategy, for innovative young company at the forefront of immunology-based drug development, founded by leading Trinity College Dublin Professors' Luke O’Neil and Kingston Mills. • Negotiated and delivered exclusive license to core and broad-reaching intellectual property from Amgen Inc., and two EU universities, underpinning successful €23m Series B. • Delivered clinical trials agreements for Phase I and Phase II clinical development of lead mAb for renal transplant and MDS. RADISENS DIAGNOSTICS LTD (2009-2012) | POINT-OF-CARE DIAGNOSTICS | BUSINESS DEVELOPMENT • Managed business development, sales & marketing for innovative start-up company, developing photonic sensor-based microfluidic technology for medical point-of-care diagnostics.• Drove early commercial engagement with UK NHS and two global manufacturers, to secure commercial validation and drive revenue. ALIMENTARY HEALTH LTD (2009-2012) | PROBIOTICS | BUSINESS DEVELOPMENT & LICENSING• Interim member of commercial management team, bridging the gap between R&D and commercialization - successfully translating research into new pipeline of products for own brand and licensing. INSTITUTE OF TECHNOLOGY, SLIGO (2007-2010) | FOOD | BUSINESS DEVELOPMENT & LICENSING• Consolidated a strong patent portfolio and managed the international prosecution, through collaborative stakeholder engagement with Technology Transfer Office and principle scientists. • Delivered a global exclusive license agreement, for an antimicrobial formulation, with US Healthcare Company Hemcon Inc.

Strategic leadership and delivery of operations, business development and sales & marketing for Luxcel Biosciences Ltd; award winning global leader in the development and productization of optical sensor technologies. LEADERSHIP & STRATEGY:• Drove a successful commercial reset for the business, culminating in its acquisition by global life sciences and healthcare leader Agilent Technologies Inc• Re-negotiated anchor commercial manufacturing and supply agreements with MOCON Inc. (leading US manufacturer of permeation and package testing instruments), freeing up essential internal R&D resources to focus on new pipeline product development• Developed new business plan, winning almost €4 million SME / innovation program funding (EU Horizon 2020), supporting product development and fast track commercialization of pipeline product solutions in the growth market of cell metabolism• Established global sales channel, comprising select regional distributors augmented with OEM agreements with three leading global reagent suppliers, delivering more than 50% YOY sales revenue growth PEOPLE MANAGEMENT:• Built, grew and mentored a highly effective sales & marketing team

Founding scientist of cancer drug discovery start-up EiRx Therapeutics. Progressive leadership and entrepreneurial career, culminating in commercial success, as CEO, leading the public listing on UK stock-market. TEAM BUILDING & TECHNOLOGY• Built, grew and mentored a motivated and results-orientated 22-strong R&D team • Led the development of a novel, patented suite of technologies to leverage a world-leading apoptosis biology, resulting in more than 100 patented ‘drug target’ products, for in-house development and licensingLEADERSHIP & COMMERCIALIZATION• Led a successful restructuring and refocusing of the company strategy, translating high quality research engine into commercially focused growth business• Steered Company through a public listing on the UK LSE Alternative Investment Market (AIM), to raise profile and facilitate future M&A• Delivered first major business deal, licensing 4 drug targets to the pharmaceutical company OSIP, Inc. for $18.4M in up-front and milestones

• Pioneered the integration of state-of-art molecular biology and genomics technologies into Sanofi-Aventis' mainstream global drug discovery process, to rapidly generate new drug target pipelines. • Co-managed major internal drug discovery program through research to pre-clinical lead chemistry.• Commissioned new molecular biology lab and developed team of 7 scientists.

Study of inflammatory mediators in Leukemia, and development of a PCR-based subtractive hybridization method to study genes associated with the commitment of stem cells to hematopoiesis.